Showing 2671-2680 of 7278 results for "".
- Study: Melanoma Declining Among Ages 30-59 in Swedenhttps://practicaldermatology.com/news/study-melanoma-declining-among-ages-30-59-sweden/2468114/Melanoma incidence and mortality rates have declined in recent years among 30- to 59-year-olds in Sweden, according to a recent study published in JAMA Dermatology. A cohort study involving Sweden’s entire population found a continuous rise in primary invasive cutaneous melanoma incidence
- Report: Global Skin Cancer Treatment Market to Hit $14.5 Billion by 2031https://practicaldermatology.com/news/global-skin-cancer-treatment-market-poised-rapid-growth-expected-hit-145-billion-2031/2468065/A recent report from Allied Analytics said the global skin cancer treatment market is projected to nearly double, reaching $14.5 billion by 2031, driven by an increasing incidence of skin cancer and advancements in treatment options. The $7.2 billion (2021) treatment market, according to t
- Analysis Shows High Incidence of Skin Eruptions with Tebentafusp in Uveal Melanomahttps://practicaldermatology.com/news/high-incidence-skin-eruptions-tebentafusp-uveal-melanoma/2468062/Tebentafusp-associated skin toxicity was prevalent in patients treated for metastatic uveal melanoma, a recent study reported. Study researchers looked at a cohort study of 33 patients treated with tebentafusp and identified skin symptoms in 26 patients (median follow-up of 21.5 months for
- Study Explores Potential of GLP-1 Agonists for Skin Disease Managementhttps://practicaldermatology.com/news/study-explores-potential-glp-1-agonists-skin-disease-management/2468016/Recent research highlights the potential of GLP-1 agonists in managing dermatological conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease, especially in patients with obesity or type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (G
- Genome-Wide Study Reveals Genetic Correlation Between Melanoma Subtypeshttps://practicaldermatology.com/news/genome-wide-study-reveals-genetic-correlation-between-melanoma-subtypes/2467851/Data from a recent genome-wide association study (GWAS) looking at the genetic underpinnings of in situ and invasive melanoma show significant shared genetic architecture between the two. Researchers for the study used data from four population-based genetic cohorts, including the UK Bio
- GUIDE: Guselkumab Dosing Every 16 Weeks Maintains Psoriasis Controlhttps://practicaldermatology.com/news/guide-guselkumab-dosing-every-16-weeks-maintains-psoriasis-control/2467730/Results from the GUIDE clinical trial showed that an extended dosing interval of guselkumab was effective for the treatment of moderate-to-sever plaque psoriasis. "Psoriasis is a chronic, systemic immune-mediated disease, predominately characterized by skin plaques, "the researchers wrote
- Five-Year Study Validates Dupilumab for Atopic Dermatitis Managementhttps://practicaldermatology.com/news/five-year-study-validates-dupilumab-atopic-dermatitis-management/2467714/New research has provided evidence of benefit from a long-term strategy of dupilumab for the treatment of atopic dermatitis (AD). Researchers for the multicenter cohort study looked at clinical effectiveness, response times, and reasons for discontinuation of dupilumab treatment over a pe
- Consensus Statement: New Reporting Measures Aim to Improve CSCC Researchhttps://practicaldermatology.com/news/consensus-statement-new-reporting-measures-aim-improve-cscc-research/2467669/A new consensus statement from an expert panel supports the creation of standardized guidelines for retrospective studies on cutaneous squamous cell carcinoma (CSCC). "Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology a
- FDA Issues Warning to Matte Beauty Over Unapproved Chemical Peelshttps://practicaldermatology.com/news/fda-issues-warning-matte-beauty-over-unapproved-chemical-peels/2467661/The U.S. Food and Drug Administration (FDA) recently sent a warning letter to Matte Beauty, addressing what the agency described as significant regulatory violations regarding their chemical peel products. According to the July 25 letter, the products in question include “TCA 100% Skin Pe
- Nemolizumab Meets Key Endpoints in ARCADIA Studieshttps://practicaldermatology.com/news/nemolizumab-meets-key-endpoints-arcadia-studies/2467533/Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, showed efficacy for the treatment of atopic dermatitis, particularly pruritus and sleep disturbance, according to an announcement from Galderma. The full results of the phase III ARCADIA 1 and 2 trials for nemolizumab were pu